MedTrace Logo

The New ICU Prognostic Score APACHE-INf

NCT05955547 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2023-07-21

No results posted yet for this study

Summary

Intensive care units (ICUs) aim to provide specialized care for patients with high morbidity and mortality risks. To effectively identify patients requiring urgent diagnosis and treatment, various scoring systems have been developed, including APACHE-II. However, these systems primarily focus on evaluating organ dysfunction and do not consider the patient's nutritional status or the role of inflammation. Recent studies have highlighted the crucial role of inflammation in patient outcomes, emphasizing the need to incorporate inflammatory parameters into scoring systems for accurate prognosis prediction. Additionally, nutritional status upon ICU admission has been largely overlooked in current scoring systems, despite its significant impact on patient outcomes. Malnourished patients have higher risks of complications, prolonged hospital stays, and increased mortality rates. Adequate nutrition supports immune function, tissue repair, and the response to therapeutic interventions, ultimately minimizing complications. Integrating nutritional assessment into existing scoring systems allows for early identification of malnourished patients and timely interventions, improving overall care quality in the ICU. Considering the importance of inflammation and nutritional status, this study aims to develop a new scoring system by adding inflammatory and nutritional parameters to APACHE II score. This comprehensive approach holds promise for enhancing patient outcomes, accurately evaluating clinical severity, and facilitating immediate interventions in critical care settings.

Conditions

Interventions

OTHER

Prognosis Scoring

To determine the prognosis of patients admitted to ICU with a scoring system that includes inflammation and nutritional status

Sponsors & Collaborators

  • Nermin Kelebek Girgin

    collaborator UNKNOWN

  • Ayşegül Özkan

    collaborator UNKNOWN

  • Gülbahar Çalışkan

    collaborator UNKNOWN

  • Bursa City Hospital

    lead OTHER_GOV

Principal Investigators

  • Nizameddin Koca, MD · University of Health Sciences, Bursa Sehir Training & Research Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2023-07-31
Completion
2023-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05955547 on ClinicalTrials.gov